Caxton Associates (New York)’s Vanda Pharmaceuticals VNDA Stock Holding History

Caxton Associates (New York)’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-192,884	Closed	-$833K	–	549
2023 Q3	$833K	Buy	192,884 +151,344	+364%	+$841K	0.11%	180
2023 Q2	$274K	Sell	41,540 -111,844	-73%	-$717K	0.04%	357
2023 Q1	$1.04M	Buy	153,384 +23,759	+18%	+$167K	0.16%	136
2022 Q4	$958K	Buy	129,625 +14,274	+12%	+$139K	0.06%	118
2022 Q3	$1.14M	Buy	115,351 +3,001	+3%	+$31.7K	0.15%	89
2022 Q2	$1.23M	Buy	112,350 +71,049	+172%	+$736K	0.12%	82
2022 Q1	$467K	Buy	+41,301	New	+$543K	0.04%	268

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Caxton Associates (New York)'s VNDA Position: Q4 2023 in Review

Caxton Associates (New York) sold out of Vanda Pharmaceuticals (VNDA) in Q4 2023, closing a stake of 192,884 shares — an estimated $833K sold.

Caxton Associates (New York) first reported a position in VNDA in Q1 2022 and held it in 7 quarters. The position peaked at $1.23M in Q2 2022. 157 funds tracked by Wall St. Rank hold VNDA as of Q4 2023.

Caxton Associates (New York) reported no remaining Vanda Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Caxton Associates (New York) sold 192,884 Vanda Pharmaceuticals shares in Q4 2023, an estimated $833K.
Caxton Associates (New York) first reported a position in Vanda Pharmaceuticals in Q1 2022 and held it in 7 quarters.
Caxton Associates (New York)'s Vanda Pharmaceuticals position peaked at $1.23M in Q2 2022.
157 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2023.

Based on Caxton Associates (New York)'s 13F filing for Q4 2023, filed 14 Feb 2024.